1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Discovery Stage Partnering Terms and Agreements

Discovery Stage Partnering Terms and Agreements

  • March 2015
  • -
  • Currentpartnering
  • -
  • 3998 pages

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 3,000 links to online copies of actual discovery stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery stage compounds/products.

Chapter 3 provides an overview of discovery stage deals strategy and deal structure including numerous case studies, whilst Chapter 4 gives an overview of the various payment strategies used in discovery stage deals.

Chapter 5 provides a review of discovery stage deal making since 2010. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 6 provides a detailed analysis of discovery stage payment terms including average headline, upfront, milestone and royalty rates for discovery deals.

Chapter 7 presents a review of the leading discovery stage deal by headline value.

Chapter 8 provides a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of discovery stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 9 provides a comprehensive and detailed review of discovery stage partnering deals signed and announced since 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

A comprehensive directory of discovery stage partnering deals since 2010 forms Chapter 10.

The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2010.

In addition, a comprehensive appendix is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.

Table Of Contents

Discovery Stage Partnering Terms and Agreements
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

2.1. Introduction
2.2. The role of discovery stage partnering
2.2.1. In-licensing at discovery stage
2.2.2. Out-licensing at discovery stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into discovery stage partnering deals
2.4.1. Licensors reasons for entering discovery stage deals
2.4.2. Licensees reasons for entering discovery stage deals
2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure

3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma - 4SC
3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case study: Incyte - Agenus Bio
3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Servier - GeNeuro
3.2.2.1.b. Case study: Teva - Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca - Ardelyx
3.2.2.1.d. Case study: Baxter - Onconova Therapeutics
3.3. Early and later stage partnering - a risk/cost comparison
3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.6.1.a. Case study : Pfizer - Spark Therapeutics
3.6.1.b. Case study : Contrafect - Trellis Bioscience
3.7. Multicomponent discovery stage partnering agreements
3.7.1.a. Example multicomponent early stage clauses
3.7.1.a. Case study: Tracon -Boehringer Ingelheim - Macrogenics
3.7.1.b. Case study: Fibrocell Science - Intrexon

Chapter 4 - Discovery stage partnering payment strategies

4.1. Introduction
4.2. Discovery stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. RandD funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making

5.1. Introduction
5.2. Discovery stage partnering over the years
5.2.1.. Attributes of discovery deals
5.3. Big pharma discovery stage dealmaking activity
5.4. Big biotech discovery stage dealmaking activity
5.5. Discovery stage partnering by deal type
5.6. Discovery stage partnering by disease type
5.7. Discovery stage partnering by technology type

Chapter 6 - Average payment terms for discovery stage partnering

6.1. Introduction
6.2. Guidelines for discovery stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Discovery stage payment terms - deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Discovery stage headline values
Figure 17: Discovery stage deals with a headline value- 2010
Figure 18: Discovery stage deals with a headline value- 2011
Figure 19: Discovery stage deals with a headline value- 2012
Figure 20: Discovery stage deals with a headline value- 2013
Figure 21: Discovery stage deals with a headline value- 2014
Figure 22: Discovery stage deals with a headline value- 2015
Figure 23: Discovery stage deal headline value distribution, US$million
Figure 24: Summary median headline value for discovery stage of development, 2010-2015
6.4.2. Discovery stage upfront payments
Figure 25: Discovery stage deals with upfront payment values- 2010
Figure 26: Discovery stage deals with upfront payment values- 2011
Figure 27: Discovery stage deals with upfront payment values- 2012
Figure 28: Discovery stage deals with upfront payment values- 2013
Figure 29: Discovery stage deals with upfront payment values- 2014
Figure 30: Discovery stage deals with upfront payment values- 2015
Figure 31: Discovery stage deal upfront payment distribution, US$million
Figure 32: Summary median upfront payments discovery stage of development, 2010-2015
6.4.3. Discovery stage milestone payments
Figure 33: Discovery stage deals with milestone payments -2010
Figure 34: Discovery stage deals with milestone payments -2011
Figure 35: Discovery stage deals with milestone payments -2012
Figure 36: Discovery stage deals with milestone payments -2013
Figure 37: Discovery stage deals with milestone payments -2014
Figure 38: Discovery stage deals with milestone payments -2015
Figure 39: Discovery stage deal milestone distribution, US$million
6.4.4. Discovery stage royalty rates
Figure 40: Discovery stage deals with royalty rates, %- 2010
Figure 41: Discovery stage deals with royalty rates, %- 2011
Figure 42: Discovery stage deals with royalty rates, %- 2012
Figure 43: Discovery stage deals with royalty rates, %- 2013
Figure 44: Discovery stage deals with royalty rates, %- 2014
Figure 45: Discovery stage deals with royalty rates, %- 2015
Figure 46: Discovery stage deal royalty rate distribution, US$million
Figure 47: Summary median royalty rate for discovery stage of development, 2010-2015

Chapter 7 - Leading discovery stage deals

7.1. Introduction
7.2. Top discovery stage deals by value

Chapter 8 - Big pharma and big biotech discovery stage partnering deals

8.1. Introduction
8.2. How to use big pharma/big biotech discovery stage partnering deals
8.3. Big pharma discovery stage partnering company profiles
8.4. Big biotech discovery stage partnering company profiles

Chapter 9 - Discovery stage partnering contracts directory

9.1. Introduction
9.2. Company A-Z
9.3. By deal type
9.4. By therapy area

Chapter 10 - Discovery stage dealmaking directory by year

10.1. Introduction
10.2. Discovery stage deals - 2010
10.3. Discovery stage deals - 2011
10.4. Discovery stage deals - 2012
10.5. Discovery stage deals - 2013
10.6. Discovery stage deals - 2014
10.7. Discovery stage deals - 2015
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Upgrades to subscription access products
Order Form - Reports

View the accompanying volume for:

Appendices
Introduction
Appendix 1 - Directory of discovery stage deals by company A-Z 2010-2015
Appendix 2 - Directory of discovery stage deals by deal type 2010-2015
Appendix 3 - Directory of discovery stage deals by therapy area 2010-2015
Appendix 4 - Partnering resource center
Online partnering
Partnering events
Further reading on dealmaking

Table of figures

Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Agreements signed by phase of development (2010-2015), % of all deals where stage disclosed
Figure 3: Components of the pure licensing deal structure
Figure 4: Payment options for discovery stage partnering deals
Figure 5: Issues affecting royalty rates
Figure 6: Discovery stage partnering frequency 2010-2015
Figure 7: Big pharma - top 50 - discovery stage deals 2010 to 2015
Figure 8: Big pharma discovery stage deal frequency - 2010 to 2015
Figure 9: Big biotech - top 50 - discovery stage deals 2010 to 2015
Figure 10: Big biotech discovery stage deal frequency - 2010 to 2015
Figure 11: Discovery stage partnering by deal type since 2010
Figure 12: Discovery stage partnering by disease type since 2010
Figure 13: Discovery stage partnering by technology type since 2010
Figure 14: Review of median upfront payments for discovery stage deals
Figure 15: Review of median milestone payments for discovery stage deals
Figure 16: Review of median royalty payments for discovery stage deals
Figure 17: Discovery stage deals with a headline value- 2010
Figure 18: Discovery stage deals with a headline value- 2011
Figure 19: Discovery stage deals with a headline value- 2012
Figure 20: Discovery stage deals with a headline value- 2013
Figure 21: Discovery stage deals with a headline value- 2014
Figure 22: Discovery stage deals with a headline value- 2015
Figure 23: Discovery stage deal headline value distribution, US$million
Figure 24: Summary median headline value for discovery stage of development, 2010-2015
Figure 25: Discovery stage deals with upfront payment values- 2010
Figure 26: Discovery stage deals with upfront payment values- 2011
Figure 27: Discovery stage deals with upfront payment values- 2012
Figure 28: Discovery stage deals with upfront payment values- 2013
Figure 29: Discovery stage deals with upfront payment values- 2014
Figure 30: Discovery stage deals with upfront payment values- 2015
Figure 31: Discovery stage deal upfront payment distribution, US$million
Figure 32: Summary median upfront payments discovery stage of development, 2010-2015
Figure 33: Discovery stage deals with milestone payments -2010
Figure 34: Discovery stage deals with milestone payments -2011
Figure 35: Discovery stage deals with milestone payments -2012
Figure 36: Discovery stage deals with milestone payments -2013
Figure 37: Discovery stage deals with milestone payments -2014
Figure 38: Discovery stage deals with milestone payments -2015
Figure 39: Discovery stage deal milestone distribution, US$million
Figure 40: Discovery stage deals with royalty rates, %- 2010
Figure 41: Discovery stage deals with royalty rates, %- 2011
Figure 42: Discovery stage deals with royalty rates, %- 2012
Figure 43: Discovery stage deals with royalty rates, %- 2013
Figure 44: Discovery stage deals with royalty rates, %- 2014
Figure 45: Discovery stage deals with royalty rates, %- 2015
Figure 46: Discovery stage deal royalty rate distribution, US$million
Figure 47: Summary median royalty rate for discovery stage of development, 2010-2015
Figure 48: Top discovery stage deals that exceeds $1 billion in deal value since 2010

For the full list of companies mentioned in the report, please contact enquiry@currentpartnering.com

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global bioinformatics market is projected to reach USD 16.18 billion by 2021 from USD 6.21 billion in 2016, growing at a CAGR of 21.1% during the forecast period. In this report, the bioinformatics ...

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.